Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $1000.0.

  • Vivos Therapeutics' Non-Current Deffered Revenue fell 9943.82% to $1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1000.0, marking a year-over-year decrease of 9943.82%. This contributed to the annual value of $97000.0 for FY2024, which is 6643.6% down from last year.
  • Per Vivos Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $1000.0 for Q3 2025, which was down 9943.82% from $5000.0 recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Non-Current Deffered Revenue high stood at $533000.0 for Q1 2024, and its period low was $1000.0 during Q3 2025.
  • Over the past 5 years, Vivos Therapeutics' median Non-Current Deffered Revenue value was $250000.0 (recorded in 2023), while the average stood at $236235.3.
  • In the last 5 years, Vivos Therapeutics' Non-Current Deffered Revenue surged by 15803.57% in 2023 and then crashed by 9943.82% in 2025.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Non-Current Deffered Revenue stood at $343000.0 in 2021, then crashed by 67.35% to $112000.0 in 2022, then surged by 158.04% to $289000.0 in 2023, then plummeted by 66.44% to $97000.0 in 2024, then crashed by 98.97% to $1000.0 in 2025.
  • Its Non-Current Deffered Revenue was $1000.0 in Q3 2025, compared to $5000.0 in Q2 2025 and $22000.0 in Q1 2025.